Big pharma CEOs usually remain tight-lipped when asked about their M&A plans but Sanofi’s Paul Hudson and his new chief financial officer, François Roger, have stressed that the French major has both the money and desire to do more deals.
Sanofi Happy To Spend To Hit Immunology Top Spot
CEO Paul Hudson has declared that “immunology is effectively our obesity” and the French firm is looking to use its position of strength in the space and its healthy cash pile to bring in early-stage assets.
More from Deals
• By
Merck & Co., which already has an oral PCSK9 inhibitor in Phase III, licensed Hengrui’s Lipoprotein(a)-lowering small molecule HRS-5346 outside of Greater China for $200m up front.
• By
South Korea's LigaChem is kickstarting a growth and globalization drive through a potential future acquisition of UK ADC player IKSUDA.
• By
The obesity market leader is teaming up with China’s United Bio-Technology to develop a product they believe could beat Lilly’s late-stage same-class candidate retatrutide.
• By
UK pharma will invest $2.5bn in Beijing R&D hub, build a vaccine manufacturing site with BioKangtai, and partner in chronic disease with Syneron and in oncology/immunology with Harbour BioMed.